ArticlebioRxiv : the preprint server for biology2024
Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer.
Joan Jacob, Yasuaki Anami, Peyton High, Zhengdong Liang, Shraddha Subramanian, Sukhen C Ghosh, Solmaz AghaAmiri, Cara Guernsey-Biddle, Ha Tran, Julie H Rowe and 3 more
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors.
Joan JacobCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX.ORCID 0000-0002-9756-8449 Yasuaki AnamiTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX.
Peyton HighCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX.ORCID 0000-0002-4318-4490 Zhengdong LiangCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX.
Shraddha SubramanianCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX.ORCID 0000-0002-7351-5924 Sukhen C GhoshCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX.ORCID 0000-0003-4602-465X Solmaz AghaAmiriCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX.ORCID 0000-0002-8472-3905 Cara Guernsey-BiddleCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX.
Ha TranCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX.
Julie H RoweDepartment of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX.
Ali AzhdariniaCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX.ORCID 0000-0001-8000-907X Kyoji TsuchikamaTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX.ORCID 0000-0002-2359-0408 Kendra S CarmonCenter for Translational Cancer Research, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX.ORCID 0000-0002-3244-6096 Funding
Mechanisms and therapeutic targeting of colon cancer stem cell plasticityR01CA226894 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CARMON, KENDRA S. · 2018 to 2022
$1.8MTraining Interdisciplinary Pharmacology Scientists (TIPS)T32GM139801 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Carmen W. Dessauer · 2021 to 2026
$1.5MNovel Antibody-Drug Conjugate Combination Therapy for Treating Colorectal CancerR21CA270716 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CARMON, KENDRA S. · 2022 to 2023
$397kNCI NIH HHS R01 CA226894NCI NIH HHS R21 CA270716NIGMS NIH HHS T32 GM139801
6 · The paper itselfAbstract
As colorectal cancer (CRC) remains a leading cause of cancer-related death, identifying therapeutic targets and approaches is essential to improve patient outcomes. The EGFR ligand epiregulin (EREG) is highly expressed in RAS wildtype and mutant CRC with minimal expression in normal tissues, making it an attractive target for antibody-drug conjugate (ADC) development. In this study, we produced and purified an EREG monoclonal antibody (mAb), H231, that had high specificity and affinity for human and mouse EREG. H231 also internalized to lysosomes, which is important for ADC payload release. ImmunoPET and
Indexed as
antibody-drug conjugatecolorectal cancerEpiregulinpatient-derived xenograft modelsRAS
Identifiers
PMID39605519
PMCPMC11601497
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390